Azitra (AZTR) vs FibroBiologics (FBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
FibroBiologics is the larger company by market cap ($8.0 million vs $7.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZTR | FBLG |
|---|---|---|
| Share price | $0.1299 | $1.13 |
| Market cap | $7.87M | $8.00M |
| 1-day change | -1.59% | +1.80% |
| EPS (TTM) | $-0.28 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.09 | $9.66 |
| 52-week low | $0.10 | $0.62 |
| Distance from 52-week high | -88.08% | -88.30% |
| Analyst consensus | buy | none |
| Avg. price target upside | +415.78% | +1006.19% |
| Average volume | 1.67M | 206.10K |
| Shares outstanding | 60.60M | 7.08M |
| Employees | 13 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Azitra
AZTR stock →Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
AZTR vs FBLG FAQ
Which is bigger, Azitra or FibroBiologics?
FibroBiologics (FBLG) is larger, with a market capitalization of $8.00M compared with $7.87M for Azitra (AZTR).
Are Azitra and FibroBiologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.